423,285 Shares in Kenvue Inc. $KVUE Bought by Gabelli Funds LLC

Gabelli Funds LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 423,285 shares of the company’s stock, valued at approximately $7,302,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kenvue during the 2nd quarter worth about $6,528,000. Jump Financial LLC increased its holdings in Kenvue by 210.6% in the 2nd quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock valued at $1,147,000 after buying an additional 37,170 shares during the period. AXA S.A. increased its holdings in Kenvue by 21.1% in the 2nd quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after buying an additional 8,524 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Kenvue by 219.1% in the 2nd quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after purchasing an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after purchasing an additional 10,885 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 1.0%

Shares of KVUE opened at $17.33 on Thursday. The firm’s 50 day simple moving average is $17.42 and its 200 day simple moving average is $17.39. The company has a market capitalization of $33.27 billion, a P/E ratio of 20.38, a P/E/G ratio of 1.30 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $24.35.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same period last year, the business earned $0.24 earnings per share. The business’s quarterly revenue was up 4.5% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be issued a $0.2075 dividend. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Analyst Upgrades and Downgrades

Several research firms recently commented on KVUE. Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 8th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. UBS Group decreased their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Canaccord Genuity Group boosted their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.33.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.59% of the company’s stock.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.